Edition:
United States

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

75.57USD
15 Dec 2017
Change (% chg)

$1.23 (+1.65%)
Prev Close
$74.34
Open
$75.08
Day's High
$75.73
Day's Low
$74.10
Volume
8,117,586
Avg. Vol
2,793,938
52-wk High
$86.26
52-wk Low
$63.76

Chart for

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS),... (more)

Overall

Beta: 1.14
Market Cap(Mil.): $98,688.84
Shares Outstanding(Mil.): 1,305.93
Dividend: 0.52
Yield (%): 2.75

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Galapagos Exercises Co-Promotion Option For Filgotinib

* SAID ON THURSDAY IT WILL OPT-IN ON CO-PROMOTION OF FILGOTINIB WITH COLLABORATION PARTNER GILEAD SCIENCES IN EIGHT EUROPEAN COUNTRIES, SHOULD FILGOTINIB BE APPROVED FOR COMMERCIAL SALE

Dec 15 2017

Gilead's new drug keeps 56 percent of lymphoma trial patients alive

More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday.

Dec 10 2017

'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study

More than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving bluebird bio Inc's experimental gene-modifying immunotherapy in a small, early stage study, according to updated data released on Sunday.

Dec 10 2017

'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study

Dec 10 More than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving bluebird bio Inc's experimental gene-modifying immunotherapy in a small, early stage study, according to updated data released on Sunday.

Dec 10 2017

Gilead's new drug keeps 56 pct of lymphoma trial patients alive

Dec 10 More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday.

Dec 10 2017

Gilead to buy Cell Design Labs for up to $567 million

Drugmaker Gilead Sciences Inc said on Thursday it was acquiring privately-held Cell Design Labs Inc for up to $567 million, giving it access to new technology platforms that would help in the development of cancer drugs.

Dec 07 2017

BRIEF-Gilead Sciences and Kite To Acquire Cell Design Labs

* GILEAD SCIENCES INC - DEAL FOR UP TO APPROXIMATELY $567 MILLION

Dec 07 2017

UPDATE 1-Gilead to buy Cell Design Labs for up to $567 mln

Dec 7 Drugmaker Gilead Sciences Inc said on Thursday it was acquiring privately-held Cell Design Labs Inc for up to $567 million, giving it access to new technology platforms that would help in the development of cancer drugs.

Dec 07 2017

REFILE-Gilead to buy Cell Design Labs for up to $567 million

Dec 7 Drugmaker Gilead Sciences Inc said on Thursday it had agreed to acquire privately-held Cell Design Labs Inc for up to $567 million to boost its CAR-T cancer drug pipeline.

Dec 07 2017

BRIEF-X-Chem And Gilead Announce Drug Discovery Collaboration

* ‍X-CHEM-AS PER AGREEMENT, CO TO SCREEN PROPRIETARY DEX(TM) LIBRARIES TO DISCOVER THERAPEUTIC LEADS AGAINST TARGETS IN ANTIVIRAL, ADDITIONAL THERAPEUTIC AREAS​

Nov 28 2017

Earnings vs. Estimates